We understand that your research needs require the flexibility to test your compounds in different cancer cell types simultaneously and in parallel. Therefore, at cpo, we offer you the ability to choose from our available PD3D® cells to mix and match your own plates.
With more than 400 proprietary patient-derived 3D (PD3D®) cell cultures, we offer you the opportunity to test your compounds in an extensive screening approach in an up to 384 well format. Together with our partner EPO matched pairs of our proprietary PD3Ds and corresponding patient-derived xenograft (PDX) are available so that your compound development can seamlessly move from in vitro to in vivo testing.
All our assays in PD3Ds can be used for a variety of preclinical analyses: compounds can be assessed for potency and selectivity, their mode of action can be identified, multi-drug combination studies can be performed and resistance analyzed.
Get a phenomic readout of PD3D formation and viability in 3D, compatible to standard cytotoxic screening assays.
Our screening format is scalable from standard 6 well plates to 384 well plates allowing adjustment for your scientific aims and platforms.
Plates are delivered frozen for long term storage and convenience, ideal for flexible experimental planning.
Our scientists are highly trained to perform patient-derived 3D cell culture assays using the PD3Ds™. And by planing the experiments together with you, you will achieve the best possible data.